SBIO
Price
$50.93Alerts
Change
-$1.60 (-3.05%)
Updated
Nov 20, 04:59 PM (EDT)
Net Assets
180.57M
Intraday BUY SELL Signals
XBI
Price
$140.38Alerts
Change
-$3.74 (-2.60%)
Updated
Nov 20, 04:59 PM (EDT)
Net Assets
9.74B
Intraday BUY SELL Signals
Interact to see
Advertisement

SBIO vs XBI

SBIO vs XBI Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 21, 2026

Which ETF would AI Choose? ALPS Medical Breakthroughs ETF (SBIO) vs. SPDR S&P Biotech ETF (XBI)

Key Takeaways

  • SBIO targets small- and mid-cap biotechnology companies with drugs in Phase II or Phase III of U.S. Food and Drug Administration (FDA) clinical trials, resulting in a more concentrated, higher-risk profile focused on emerging medical breakthroughs.
  • XBI provides broader exposure to the biotechnology sector through a modified equal-weighted index that includes a mix of large-, mid-, and small-cap companies, offering greater diversification across approximately 160 holdings.
  • Expense ratios differ notably, with SBIO at 0.50% and XBI at 0.35%, influencing long-term cost efficiency for investors seeking biotech sector exposure.
  • Both ETFs maintain nearly 100% allocation to healthcare, specifically biotechnology, but SBIO emphasizes earlier-stage clinical development while XBI captures a wider range of established and developing firms.
  • Liquidity and scale favor XBI, with significantly higher assets under management supporting tighter bid-ask spreads and easier trading compared to the smaller SBIO fund.
  • Structural differences position SBIO for investors seeking targeted exposure to clinical-stage innovation and XBI for those preferring balanced sector representation with lower costs.

Introduction

Biotechnology ETFs have gained relevance amid ongoing advancements in drug development, regulatory pathways, and capital allocation within the healthcare sector. SBIO and XBI both deliver pure-play exposure to U.S. biotechnology companies but pursue distinct strategies that appeal to different investor objectives. They do not compete directly as identical products; instead, they offer alternative approaches to the same thematic universe, with SBIO emphasizing smaller clinical-stage names and XBI providing broader, equal-weighted coverage across the biotech landscape. This comparison highlights how structural choices influence risk, diversification, and positioning within current market cycles.

ALPS Medical Breakthroughs ETF (SBIO) Overview

The ALPS Medical Breakthroughs ETF (SBIO) is a passive fund that tracks the S-Network Medical Breakthroughs Index. The index focuses on U.S.-listed small- and mid-cap biotechnology companies with at least one drug in Phase II or Phase III of FDA clinical trials and market capitalizations between $200 million and $5 billion. The ETF typically holds around 100 to 107 securities, with top holdings concentrated in names such as CG Oncology, Oruka Therapeutics, and Travere Therapeutics, where the top 10 positions represent approximately 30% of assets. Sector allocation stands at 100% healthcare. It carries an expense ratio of 0.50% and employs market-cap weighting within its defined universe. Distinguishing features include its strict emphasis on clinical-stage breakthroughs and exclusion of larger, more mature biotechnology firms.

SPDR S&P Biotech ETF (XBI) Overview

The SPDR S&P Biotech ETF (XBI) is a passive fund that tracks the S&P Biotechnology Select Industry Index using a modified equal-weight methodology. This approach delivers exposure across approximately 157 to 166 U.S. biotechnology companies spanning large-, mid-, and small-capitalization segments. Top holdings include Moderna, Natera, and AbbVie, with the top 10 accounting for roughly 18% of the portfolio. Sector allocation is approximately 99% healthcare with a minor financial services component. The expense ratio is 0.35%. Key characteristics encompass its equal-weighted structure, which reduces concentration risk relative to market-cap-weighted peers, and its inclusion of both established industry leaders and emerging developers.

Industry and Thematic Backdrop

The biotechnology sector continues to evolve under the influence of FDA regulatory decisions, clinical trial outcomes, and financing conditions tied to interest rate expectations. Innovation in areas such as gene editing, oncology, and rare disease treatments remains a primary catalyst, while capital flows into early-stage companies can fluctuate with broader risk sentiment. Macroeconomic factors, including healthcare policy developments and reimbursement trends, affect both established and clinical-stage firms. Sector risks encompass binary trial results, patent expirations, and competition for funding, which can amplify volatility across the biotechnology space during shifting market cycles.

Performance and Positioning Comparison

In recent market cycles, SBIO has exhibited higher volatility due to its focus on smaller clinical-stage companies, whose share prices often react sharply to trial data and funding announcements. XBI has demonstrated more balanced behavior through its equal-weighted methodology and inclusion of larger-capitalization names, providing a buffer during periods of sector rotation or earnings variability among top holdings. Relative positioning reflects differing sensitivities: SBIO tends to amplify moves tied to breakthrough announcements, while XBI offers steadier participation across the broader biotechnology ecosystem amid interest rate shifts or macroeconomic adjustments.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors comparing biotechnology exposure can leverage these capabilities to refine their analysis of funds like SBIO and XBI.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a higher probability of favor to XBI. Its lower expense ratio, broader diversification across more holdings, modified equal-weight methodology, and substantially greater liquidity profile provide advantages in cost efficiency and risk distribution within the biotechnology sector. While SBIO offers compelling targeted exposure to clinical-stage innovation, the overall combination of lower costs, scale, and balanced positioning supports a probabilistic edge for XBI in most investor scenarios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
SBIO vs. XBI commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SBIO is a Hold and XBI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for SBIO with price predictions
Nov 20, 2026

SBIO sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for SBIO moved below the 200-day moving average on November 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBIO as a result. In 69 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for SBIO turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 41 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

SBIO moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

SBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SBIO's RSI Oscillator exited the oversold zone, 26 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 277 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 211 of 230 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

A.I.Advisor
a Summary for XBI with price predictions
Nov 20, 2026

XBI's Stochastic Oscillator is remaining in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

TECHNICAL ANALYSIS
Technical Analysis
SBIOXBI
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
88%
Bullish Trend 12 days ago
90%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement

SBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SBIO has been loosely correlated with RARE. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SBIO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBIO
1D Price
Change %
SBIO100%
-3.01%
RARE - SBIO
64%
Loosely correlated
-4.30%
RCUS - SBIO
59%
Loosely correlated
-1.01%
FATE - SBIO
59%
Loosely correlated
-9.01%
ROIV - SBIO
58%
Loosely correlated
-0.78%
EDIT - SBIO
58%
Loosely correlated
-4.09%
More

XBI and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBI
1D Price
Change %
XBI100%
-2.73%
RCUS - XBI
60%
Loosely correlated
-1.01%
VYGR - XBI
59%
Loosely correlated
-4.97%
LYEL - XBI
57%
Loosely correlated
+1.62%
LGND - XBI
56%
Loosely correlated
-0.03%
MGNX - XBI
55%
Loosely correlated
-1.01%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CMBS47.740.16
+0.34%
iShares CMBS ETF (CMBS)
XCLR28.27N/A
N/A
Global X S&P 500 Collar 95-110 ETF (XCLR)
ITAN41.67-1.11
-2.58%
Sparkline Intangible Value ETF (ITAN)
SILJ18.52-1.16
-5.89%
Amplify Junior Silver Miners ETF (SILJ)
EZET12.10-1.23
-9.23%
Franklin Ethereum ETF (EZET)